Use of an IL12 receptor-beta 1 splice variant to diagnose active tuberculosis
The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M. tuberculosis infection. In another embodiment, the present invention contemplates a method of monitoring a M. tuberculosis infection. In yet another embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection. In a further embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection.
1. A method of identifying an active M. tuberculosis infection, comprising:
a) providing a patient infected with M. tuberculosis,
b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell,
c) diagnosing the patient as having an active M. tuberculosis infection if the amount of IL12Rβ1 isoform 2 mRNA is greater than the amount of IL12Rβ1 isoform 1 mRNA,
d) initiating a therapeutic treatment on said patient with an active M. tuberculosis infection.
2. The method of claim 1 , wherein said cell is a peripheral blood mononuclear cell.
3. The method of claim 1 , wherein the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA is determined by PCR.
4. The method of claim 3 , wherein said PCR is real-time PCR.
5. The method of claim 1 , wherein the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA is determined by microarray transcriptional analysis.
6. A method of identifying an active M. tuberculosis infection, comprising:
a) providing a patient suspected of being infected with M. tuberculosis,
b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell,
c) diagnosing the patient as having an active M. tuberculosis infection if the amount of IL12Rβ1 isoform 2 mRNA is greater than the amount of IL12Rβ1 isoform 1 mRNA,
d) initiating a therapeutic treatment on said patient with an active M. tuberculosis infection.
7. A method of monitoring a M. tuberculosis infection, comprising:
a) providing a patient infected with M. tuberculosis,
b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell,
c) diagnosing the patient as having an active M. tuberculosis infection if the amount of IL12Rβ1 isoform 2 mRNA is greater than the amount of IL12Rβ1 isoform 1 mRNA,
d) diagnosing the patient as having a latent M. tuberculosis infection if the amount of IL12Rβ1 isoform 1 mRNA is greater than the amount of IL12Rβ1 isoform 2 mRNA,
c) initiating a therapeutic treatment if the patient has an active M. tuberculosis infection.
8. The method of claim 7 , wherein said cell is a peripheral blood mononuclear cell.
9. The method of claim 7 , wherein the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA is determined by PCR.
10. The method of claim 9 , wherein said PCR is real-time PCR.
11. The method of claim 7 , wherein the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA is determined by microarray transcriptional analysis.
12. A method of monitoring a patient's response to treatment for an active M. tuberculosis infection, comprising:
a) providing a patient with an active M. tuberculosis infection,
b) initiating a therapeutic treatment on said patient,
b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient, wherein said cell is a peripheral blood mononuclear cell, and
c) continuing said therapeutic treatment if the ratio of IL12Rβ1 isoform 1 mRNA to IL12Rβ1 isoform 2 mRNA increases.
13. The method of claim 12 , wherein said therapeutic treatment is determined to be effective if the ratio of IL12Rβ1 isoform 2 mRNA to IL12Rβ1 isoform 1 mRNA decreases.
14. The method of claim 12 , wherein said cell is a peripheral blood mononuclear cell.
15. The method of claim 12 , wherein the amount of IL12Rβ1 isoform 1mRNA and IL12Rβ1 isoform 2 mRNA is determined by PCR.
16. The method of claim 15 wherein said PCR is real-time PCR.
17. The method of claim 12 , wherein the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA is determined by microarray transcriptional analysis.
18. A method of monitoring a patient's response to treatment for an active M. tuberculosis infection, comprising:
a) providing a patient with an active M. tuberculosis infection,
b) initiating a therapeutic treatment on said patient,
b) determining the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA in a cell from said patient during the course of said treatment, wherein said cell is a peripheral blood mononuclear, and
c) diagnosing said patient as responding to said treatment when the ratio of IL12Rβ1 isoform 2 mRNA to IL12Rβ1 isoform 1 mRNA decreases.
19. The method of claim 18 , wherein said cell is a peripheral blood mononuclear cell.
20. The method of claim 18 , wherein the amount of IL12Rβ1 isoform 1mRNA and IL12Rβ1 isoform 2 mRNA is determined by PCR.
21. The method of claim 20 wherein said PCR is real-time PCR.
22. The method of claim 18 , wherein the amount of IL12Rβ1 isoform 1 mRNA and IL12Rβ1 isoform 2 mRNA is determined by microarray transcriptional analysis.